Trials / Recruiting
RecruitingNCT05823285
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
A Phase 1 Study to Investigate the Safety, Tolerability，Pharmacokinetics, Immunogenicity and Preliminary Effectiveness of QLS31903 Injection in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS31903 | 0.01μg/kg-2.16 μg/kg QLS31903 for injection |
Timeline
- Start date
- 2023-03-22
- Primary completion
- 2025-06-15
- Completion
- 2027-06-15
- First posted
- 2023-04-21
- Last updated
- 2023-04-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05823285. Inclusion in this directory is not an endorsement.